The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol.
BACKGROUND
The current obesity epidemic is thought to be partly driven by over-consumption of sugar-sweetened diets and soft drinks. Loss-of-control over eating and addiction to drugs of abuse share overlapping brain mechanisms including changes in motivational drive, such that stimuli that are often no longer 'liked' are still intensely 'wanted' [7], . The neurokinin 1 (NK1) receptor system has been implicated in both learned appetitive behaviors and addiction to alcohol and opioids; however, its role in natural reward seeking remains unknown.


RESULTS
We sought to determine whether the NK1-receptor system plays a role in the reinforcing properties of sucrose using a novel selective and clinically safe NK1-receptor antagonist, ezlopitant (CJ-11,974), in three animal models of sucrose consumption and seeking. Furthermore, we compared the effect of ezlopitant on ethanol consumption and seeking in rodents. The NK1-receptor antagonist, ezlopitant decreased appetitive responding for sucrose more potently than for ethanol using an operant self-administration protocol without affecting general locomotor activity. To further evaluate the selectivity of the NK1-receptor antagonist in decreasing consumption of sweetened solutions, we compared the effects of ezlopitant on water, saccharin-, and sodium chloride (NaCl) solution consumption. Ezlopitant decreased intake of saccharin but had no effect on water or salty solution consumption.


CONCLUSIONS
The present study indicates that the NK1-receptor may be a part of a common pathway regulating the self-administration, motivational and reinforcing aspects of sweetened solutions, regardless of caloric value, and those of substances of abuse. Additionally, these results indicate that the NK1-receptor system may serve as a therapeutic target for obesity induced by over-consumption of natural reinforcers.
Steensland
Pia
P
Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, California, United States of America.
Simms
Jeffrey A
JA
Nielsen
Carsten K
CK
Holgate
Joan
J
Bito-Onon
Jade J
JJ
Bartlett
Selena E
SE
D000428:Alcohol Drinking / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001596:Benzylamines / Q000008:administration & dosage*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D000431:Ethanol / Q000378:metabolism*; D006801:Humans; D006963:Hyperphagia / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D064729:Neurokinin-1 Receptor Antagonists; D051381:Rats; D020318:Rats, Long-Evans; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D012646:Self Administration; D013395:Sucrose / Q000378:metabolism*; D014867:Water / Q000378:metabolism
D001596:Benzylamines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D014867:Water; D000431:Ethanol; C413864:ezlopitant; D013395:Sucrose
Pharmacology. 2002 Nov;66(3):144-52
12372904
Psychopharmacologia. 1973;29(3):203-10
4702273
Neuropharmacology. 2002 Dec;43(8):1258-68
12527475
Neuroreport. 2001 Nov 16;12(16):3549-52
11733709
Trends Neurosci. 2003 Sep;26(9):507-13
12948663
Pharmacol Ther. 2006 Sep;111(3):855-76
16545872
Eur J Neurosci. 1998 Mar;10(3):1179-87
9753186
Circulation. 2002 Jul 23;106(4):523-7
12135957
Trends Neurosci. 2007 Aug;30(8):399-406
17629579
J Med Chem. 1992 Jul 10;35(14):2591-600
1378901
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23
17626178
Pharmacol Biochem Behav. 1997 Nov;58(3):679-82
9329058
Physiol Behav. 2005 Jan 31;84(1):73-9
15642609
Psychol Rep. 2002 Feb;90(1):58-60
11899012
Neuroscience. 2005;134(3):737-44
15987666
Brain Res. 2005 Jan 21;1031(2):194-201
15649444
J Comp Neurol. 2006 Jun 20;496(6):859-76
16628615
Physiol Behav. 2005 Mar 16;84(3):359-62
15763572
Eur J Neurosci. 2005 Jun;21(12):3301-9
16026468
J Comp Neurol. 2000 Jul 31;423(3):500-11
10870089
Psychopharmacology (Berl). 2008 Jul;199(1):109-17
18470506
Nat Neurosci. 2005 May;8(5):555-60
15856062
Biol Psychiatry. 2008 Dec 1;64(11):974-81
18774553
Appetite. 1997 Dec;29(3):325-52
9468764
Physiol Behav. 2005 Jan 31;84(1):53-63
15642607
J Addict Dis. 2004;23(3):39-53
15256343
Brain Res. 1992 Sep 4;589(2):291-301
1327413
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15641-5
17023542
Pharmacol Biochem Behav. 2002 May;72(1-2):483-90
11900823
Nature. 2000 May 11;405(6783):180-3
10821273
Alcohol Clin Exp Res. 2008 Oct;32(10):1816-23
18671810
Pharmacol Biochem Behav. 1996 Aug;54(4):693-7
8853191
J Neurosci. 2009 Jan 7;29(1):222-33
19129399
Brain Res Mol Brain Res. 2004 May 19;124(2):134-42
15135221
Biopharm Drug Dispos. 1999 Dec;20(9):429-39
10951432
Science. 2008 Mar 14;319(5869):1536-9
18276852
PLoS One. 2007 Aug 01;2(8):e698
17668074
Lancet. 2001 Feb 17;357(9255):505-8
11229668
J Neurosci. 2001 Feb 15;21(4):RC129
11160414
Obesity (Silver Spring). 2006 Aug;14 Suppl 5:197S-200S
17021366
Neurosci Biobehav Rev. 2008;32(1):20-39
17617461
Obes Res. 2001 Nov;9 Suppl 4:263S-270S
11707552
J Neurosci. 2003 Sep 10;23(23):8271-80
12967989
Behav Brain Res. 2002 Aug 21;134(1-2):123-30
12191798
Am J Clin Nutr. 1992 Jan;55(1 Suppl):151S-154S
1728825
Alcohol Clin Exp Res. 1986 Aug;10(4):436-42
3530023
Science. 1983 Aug 26;221(4613):871-3
6879185
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12533-8
18719114
Addict Biol. 2006 Mar;11(1):2-38
16759333
Neurosci Biobehav Rev. 2002 Oct;26(6):713-28
12479844
Curr Top Med Chem. 2004;4(1):39-50
14754375
Neuroscience. 2003;122(1):17-20
14596845
Obes Res. 2002 Jun;10(6):478-88
12055324
J Clin Oncol. 1999 Jan;17(1):338-43
10458252
Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R31-7
12933362
J Comp Neurol. 1994 Sep 8;347(2):249-74
7814667
Eur J Pharmacol. 2005 Jan 10;507(1-3):99-105
15659299
Science. 1998 May 29;280(5368):1371-4
9603719
Neurosci Biobehav Rev. 1996;20(1):1-25
8622814
Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):377-81
9164597
Behav Pharmacol. 2008 Dec;19(8):777-85
19020412
Neuropsychopharmacology. 2009 Oct;34(11):2442-9
19553914